CN114129635B - Antibacterial composition containing capsicum extract and its application - Google Patents
Antibacterial composition containing capsicum extract and its application Download PDFInfo
- Publication number
- CN114129635B CN114129635B CN202111266650.7A CN202111266650A CN114129635B CN 114129635 B CN114129635 B CN 114129635B CN 202111266650 A CN202111266650 A CN 202111266650A CN 114129635 B CN114129635 B CN 114129635B
- Authority
- CN
- China
- Prior art keywords
- meropenem
- extract
- drug
- bacteria
- capsicum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940007061 capsicum extract Drugs 0.000 title claims abstract description 34
- 239000001943 capsicum frutescens fruit extract Substances 0.000 title claims abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims abstract description 79
- 229960002260 meropenem Drugs 0.000 claims abstract description 76
- 239000003814 drug Substances 0.000 claims abstract description 56
- 241000894006 Bacteria Species 0.000 claims abstract description 51
- 229940116257 pepper extract Drugs 0.000 claims abstract description 18
- 235000002566 Capsicum Nutrition 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 239000001390 capsicum minimum Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000012675 alcoholic extract Substances 0.000 claims description 3
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 40
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 11
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 19
- 239000000284 extract Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000208293 Capsicum Species 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000002815 broth microdilution Methods 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000005142 microbroth dilution method Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
含辣椒提取物的抗菌组合物及其应用。本发明公开了抗菌组合物,所述抗菌组合物包括美罗培南和辣椒提取物。当将辣椒提取物与美罗培南联合用药时具有协同作用,能够显著提高对耐药菌的抑菌效果,且效果优于各自单独用药。本发明为研究中西药联合用药对耐药菌的逆转提供了方向。Antibacterial composition containing capsicum extract and application thereof. The present invention discloses an antibacterial composition comprising meropenem and capsicum extract. When the pepper extract and meropenem are used in combination, there is a synergistic effect, and the bacteriostatic effect on drug-resistant bacteria can be significantly improved, and the effect is better than that of each alone. The invention provides a direction for studying the reversal of drug-resistant bacteria by the combination of traditional Chinese and western medicines.
Description
技术领域technical field
本发明涉及生物医药技术领域,具体涉及包括美罗培南及辣椒提取物的抗菌组合物及其应用。The invention relates to the technical field of biomedicine, in particular to an antibacterial composition comprising meropenem and capsicum extract and applications thereof.
背景技术Background technique
美罗培南(meropenem)是一种新型的、人工合成的碳青霉烯类抗生素。碳青霉烯类抗生素具有较广的抗菌谱和抗菌活性,是临床上治疗严重混合感染以及耐药菌感染的有效药物,在临床应用中有较高的治疗效果。其中美罗培南通过抑制细菌细胞壁的合成,对大肠杆菌以及铜绿假单胞菌具有较好的抑制效果。但随着美罗培南在临床实践中频繁而广泛地使用,一些不合理使用的情况也逐渐发生,这在一定程度上导致了美罗培南耐药菌的出现,铜绿假单胞菌就是其中之一。铜绿假单胞菌对美罗培南的耐药性与碳青霉烯类抗菌药物的使用量存在正相关关系。碳青霉烯耐药菌株对其他抗菌药物的耐药率普遍高于碳青霉烯敏感菌株,这使得美罗培南药物的临床治疗效益逐渐降低。为解决此问题,不仅要从规范合理用药入手,还需要研究如何抑制耐药菌。有研究报道治疗耐碳青霉烯类抗生素细菌感染的潜在药物,指出其治疗药物主要有多黏菌素、替加环素、磷霉素及氨基糖苷类。但化学抗菌药容易产生耐药性,研究周期长,同时可能导致多重耐药性细菌(“超级细菌”)的出现。Meropenem (meropenem) is a new type of synthetic carbapenem antibiotics. Carbapenem antibiotics have a broad antibacterial spectrum and antibacterial activity, and are effective drugs for the clinical treatment of severe mixed infections and drug-resistant bacterial infections, and have a high therapeutic effect in clinical applications. Among them, meropenem has a good inhibitory effect on Escherichia coli and Pseudomonas aeruginosa by inhibiting the synthesis of bacterial cell walls. However, with the frequent and extensive use of meropenem in clinical practice, some irrational use has gradually occurred, which has led to the emergence of meropenem-resistant bacteria to a certain extent, and Pseudomonas aeruginosa is one of them. There is a positive correlation between the resistance of Pseudomonas aeruginosa to meropenem and the amount of carbapenem antibiotics used. The resistance rate of carbapenem-resistant strains to other antimicrobial agents is generally higher than that of carbapenem-sensitive strains, which makes the clinical benefit of meropenem gradually decrease. In order to solve this problem, it is necessary not only to standardize and rationalize drug use, but also to study how to inhibit drug-resistant bacteria. Studies have reported potential drugs for the treatment of carbapenem-resistant bacterial infections, pointing out that the main therapeutic drugs are polymyxin, tigecycline, fosfomycin and aminoglycosides. However, chemical antibacterial drugs are prone to drug resistance, and the research cycle is long, which may lead to the emergence of multi-drug resistant bacteria ("super bacteria").
中药作为一类天然药物,不仅具有低毒副作用,还有低耐药性等优点。有研究指出中药可以通过干扰耐药菌的生化代谢以直接抑制或杀灭耐药菌,或者改善细菌的耐药性以间接抑菌杀菌,以及维护机体平衡以整体调节治疗耐药菌感染。然而,不同的中药或中药提取物对细菌或耐药菌的抑制作用不同,也存在一定局限性。As a class of natural medicine, traditional Chinese medicine not only has the advantages of low toxicity and side effects, but also low drug resistance. Studies have pointed out that traditional Chinese medicine can directly inhibit or kill drug-resistant bacteria by interfering with the biochemical metabolism of drug-resistant bacteria, or improve the drug resistance of bacteria to indirectly inhibit and kill bacteria, and maintain the balance of the body to regulate and treat drug-resistant bacterial infections as a whole. However, different Chinese medicines or Chinese medicine extracts have different inhibitory effects on bacteria or drug-resistant bacteria, and there are certain limitations.
对于天然药物体外、体内和体内外联合抑菌活性的实验方法而言,不同类别天然药物的适用方法各异,因此,需要采用适当的方法,筛选出适合的针对特定菌群或耐药菌的中药或天然药物,从而针对细菌或耐药菌起到抑菌或杀菌作用。For the experimental methods of in vitro, in vivo, and combined antibacterial activities of natural medicines, the applicable methods of different types of natural medicines are different. Traditional Chinese medicine or natural medicine, so as to play a bacteriostatic or bactericidal effect on bacteria or drug-resistant bacteria.
发明内容Contents of the invention
本发明的目的在于提供抗菌组合物,能够对耐药菌起到抑菌或杀菌的作用。The object of the present invention is to provide an antibacterial composition, which can inhibit or sterilize drug-resistant bacteria.
第一方面,本发明提供抗菌组合物,所述抗菌组合物包括美罗培南和辣椒提取物。In a first aspect, the present invention provides an antibacterial composition comprising meropenem and capsicum extract.
在一些实施方案中,所述辣椒提取物为辣椒醇提物;优选地,所述辣椒提取物为辣椒的60%-80%醇提物,更优选为辣椒的70%乙醇提取物。In some embodiments, the capsicum extract is an alcoholic extract of capsicum; preferably, the capsicum extract is a 60%-80% alcoholic extract of capsicum, more preferably a 70% ethanol extract of capsicum.
在本文中,辣椒的60%-80%醇提物是指,使用60%-80%的醇(例如乙醇)对辣椒进行提取,干燥后得到的产物。Herein, the 60%-80% alcohol extract of capsicum refers to the product obtained after the capsicum is extracted with 60%-80% alcohol (such as ethanol) and dried.
在一些实施方案中,在所述抗菌组合物中,美罗培南与所述辣椒提取物的重量份比为(1~8):(1000~4000)。In some embodiments, in the antibacterial composition, the weight ratio of meropenem to the pepper extract is (1-8):(1000-4000).
优选地,美罗培南与所述辣椒提取物的重量份比为(1~4):(1000~4000),进一步优选地为(1~2):(1000~4000),更优选地重量份比为1:1000、1:2000、1:4000、1:8000、2:1000、4:1000、8:1000。Preferably, the weight ratio of meropenem to the pepper extract is (1-4):(1000-4000), more preferably (1-2):(1000-4000), more preferably the weight ratio 1:1000, 1:2000, 1:4000, 1:8000, 2:1000, 4:1000, 8:1000.
第二方面,本发明提供所述抗菌组合物在制备用于抗菌的药物中的用途。In a second aspect, the present invention provides the use of the antibacterial composition in the preparation of antibacterial drugs.
在一些实施方案中,所述菌为美罗培南耐药菌。In some embodiments, the bacteria are meropenem-resistant bacteria.
在一些实施方案中,所述耐药菌包括大肠杆菌(Escherichia coli)、铜绿假单胞菌(Pseudomonas aeruginosa)、肺炎克雷伯菌(Klebsiella pneumonia)和鲍氏不动杆菌(Acinetobacter baumannii);优选地,所述耐药菌为大肠杆菌(Escherichia coli)。In some embodiments, the drug-resistant bacteria include Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumonia, and Acinetobacter baumannii; preferably Preferably, the drug-resistant bacteria is Escherichia coli.
本发明的有益效果Beneficial effects of the present invention
为了消除细菌耐药性,本发明从中药提取物入手,通过制备生长曲线和肉汤微量稀释棋盘法试验,筛选出对美罗培南耐药菌体外抑菌作用较强的中药提取物。结果令人惊喜地发现,辣椒提取物在联合美罗培南用药时,对美罗培南耐药菌在体外有显著的抑制作用,且效果优于各自单独用药,因而美罗培南与所述辣椒提取物联合用药时具有明显的协同作用。每种物质在组合物中的相对用量大大减少,进而减少可能的不良反应和副作用,提高用药安全性,同时还可以增加患者服用的依从性,从而保证疗效。In order to eliminate bacterial drug resistance, the present invention starts with extracts of traditional Chinese medicines, and screens extracts of traditional Chinese medicines with strong antibacterial effect on meropenem-resistant bacteria in vitro by preparing growth curves and broth microdilution checkerboard tests. As a result, it was surprisingly found that when the pepper extract was used in combination with meropenem, it had a significant inhibitory effect on meropenem-resistant bacteria in vitro, and the effect was better than that of each drug alone, so the combination of meropenem and the pepper extract There is an obvious synergistic effect. The relative amount of each substance in the composition is greatly reduced, thereby reducing possible adverse reactions and side effects, improving the safety of medication, and at the same time increasing the compliance of patients taking medication, thereby ensuring curative effect.
本发明的辣椒提取物与美罗培南抗生素联用具有增效和减毒优势。辣椒提取物联合美罗培南抗生素使用能够对美罗培南耐药菌起到抑制作用。本发明为解决美罗培南日趋严重的耐药问题提供了新的研究思路和研发方向。The combined use of the capsicum extract of the present invention and the meropenem antibiotic has the advantages of synergism and attenuation. Capsicum extract combined with meropenem antibiotics can inhibit meropenem-resistant bacteria. The present invention provides a new research idea and research and development direction for solving the increasingly serious drug resistance problem of meropenem.
本发明采用微量肉汤稀释法来研究辣椒提取物联合美罗培南用药对美罗培南耐药菌的体外抑制作用,具有重大研究意义,有望对美罗培南治疗重症感染疾病研制新的辅助药提供参考,提高其治疗效益。The present invention uses a micro-broth dilution method to study the in vitro inhibitory effect of capsicum extract combined with meropenem on meropenem-resistant bacteria, which is of great research significance and is expected to provide reference for the development of new adjuvant drugs for meropenem in the treatment of severe infectious diseases and improve its therapeutic benefits.
附图说明Description of drawings
图1为辣椒提取物联合美罗培南用药的生长曲线。Figure 1 is the growth curve of pepper extract combined with meropenem.
图2为桑叶提取物联合美罗培南用药的生长曲线。Figure 2 is the growth curve of mulberry leaf extract combined with meropenem.
图3为杜仲叶提取物联合美罗培南用药的生长曲线。Figure 3 is the growth curve of Eucommia ulmoides leaf extract combined with meropenem.
图4为黄芩苷联合美罗培南用药的生长曲线。Figure 4 is the growth curve of baicalin combined with meropenem.
具体实施方式Detailed ways
以下实施例用于说明本发明,但不用来限制本发明的范围。The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.
实施例1Example 1
1.菌种与抗生素1. Bacteria and antibiotics
美罗培南耐药大肠杆菌株20a02(由本实验室从鸡场分离保存)。Meropenem-resistant Escherichia coli strain 20a02 (isolated and preserved from chicken farms by our laboratory).
质控菌株大肠杆菌(ATCC25922)(购于中国兽医药品监察所)。Quality control strain Escherichia coli (ATCC25922) (purchased from China Veterinary Drug Control Institute).
美罗培南,粉末,纯品。Meropenem, powder, pure.
2.中药提取物2. Chinese herbal extracts
辣椒提取物的制备:Preparation of capsicum extract:
取辣椒,加70%乙醇提取两次,第一次2小时,第二次1小时,提取液滤过,滤液合并,浓缩,干燥,即得。Take pepper, add 70% ethanol to extract twice, the first time is 2 hours, the second time is 1 hour, the extract is filtered, the filtrates are combined, concentrated and dried to obtain the product.
3.耐药菌与药物的制备3. Preparation of drug-resistant bacteria and drugs
3.1耐药菌的复苏3.1 Recovery of resistant bacteria
实验前一天,将耐药菌株划板接种到琼脂培养基上,37℃恒温恒湿培养箱中培养24h备用。The day before the experiment, the drug-resistant strains were inoculated on the agar medium, and cultured in a constant temperature and humidity incubator at 37°C for 24 hours.
3.2美罗培南药液的配备3.2 Preparation of meropenem liquid medicine
用电子分析天平准确称取一定量的美罗培南药粉,加入纯水溶解。配成浓度为2560μg/mL,在超净工作台中,采用注射器吸取药液,透过无菌过滤膜过滤除菌,用2mLEP管分装,-20℃冰箱保存备用。Accurately weigh a certain amount of meropenem powder with an electronic analytical balance, and add pure water to dissolve it. The prepared concentration is 2560 μg/mL. In the ultra-clean workbench, use a syringe to draw the liquid medicine, filter it through a sterile filter membrane to filter and sterilize, use 2mLEP tubes to aliquot, and store in a -20°C refrigerator for later use.
3.3中药提取物溶液的配制3.3 Preparation of traditional Chinese medicine extract solution
按照称量实验操作规范,用电子分析天平准确称取40mg辣椒提取物于10mL EP管中,加入5mL纯水配成浓度为8mg/mL的辣椒提取物溶液。在超净工作台中用5mL注射器吸取提取物溶液透过无菌过滤膜过滤除菌,并用2mLEP管分装,-20℃冰箱保存备用。According to the operating specifications of the weighing experiment, accurately weigh 40 mg of capsicum extract into a 10 mL EP tube with an electronic analytical balance, add 5 mL of pure water to prepare a solution of capsicum extract with a concentration of 8 mg/mL. Use a 5mL syringe to draw the extract solution in the ultra-clean workbench, pass it through a sterile filter membrane to filter and sterilize, and use 2mLEP tubes to aliquot it, and store it in a -20°C refrigerator for later use.
记录生长曲线实验结果,按照上述步骤配制浓度为32mg/mL的辣椒提取物溶液,作为中药提取物溶液,除菌后保存备用。Record the results of the growth curve experiment, prepare a capsicum extract solution with a concentration of 32 mg/mL according to the above steps, and use it as a traditional Chinese medicine extract solution, and store it for future use after sterilization.
4.美罗培南对耐药大肠杆菌MIC的测定4. Determination of MIC of meropenem against drug-resistant Escherichia coli
将冰箱里配制好的美罗培南药液取出,待融化至室温时使用,使用前要摇匀。将美罗培南药液稀释到初浓度为256μg/mL,采用无菌的96孔聚丙烯微量滴定板,根据美罗培南的终浓度质控菌范围(0.008μg/mL-0.06μg/mL)选取16个孔并编号,各加入100μL MHB肉汤培养基。在第一孔中加入256μg/mL的美罗培南药液100μL,混合均匀后取100μL加入第2孔,如此倍比稀释至第14孔,最后弃去100μL,然后每孔接种已经稀释好的菌液100μL,得到美罗培南药液的浓度分别为:64μg/mL、32μg/mL、16μg/mL、8μg/mL、4μg/mL、2μg/mL、1μg/mL、0.5μg/mL、0.25μg/mL、0.125μg/mL、0.0625μg/mL、0.03125μg/mL、0.015625μg/mL、0.0078125μg/mL,第15孔不加美罗培南药液但接种菌液100μL,做为阳性对照,第16孔不加美罗培南药液也不加菌液,做为阴性对照。置恒温恒湿培养箱中37℃培养24h,观察结果。接种的菌液分质控菌和实验菌,并各做两次平行实验进行验证。Take out the meropenem liquid prepared in the refrigerator and use it when it melts to room temperature. Shake well before use. Dilute the meropenem solution to an initial concentration of 256 μg/mL, use a sterile 96-well polypropylene microtiter plate, and select 16 quality control bacteria according to the final concentration range of meropenem (0.008 μg/mL-0.06 μg/mL) The wells were numbered, and 100 μL of MHB broth medium was added to each well. Add 100 μL of 256 μg/mL meropenem drug solution to the first well, mix well, take 100 μL and add it to the second well, and then dilute to the 14th well, finally discard 100 μL, and then inoculate each well with the diluted bacterial solution 100 μL, the concentrations of the meropenem solution were: 64 μg/mL, 32 μg/mL, 16 μg/mL, 8 μg/mL, 4 μg/mL, 2 μg/mL, 1 μg/mL, 0.5 μg/mL, 0.25 μg/mL, 0.125μg/mL, 0.0625μg/mL, 0.03125μg/mL, 0.015625μg/mL, 0.0078125μg/mL, no meropenem liquid was added to the 15th well, but 100μL of the bacterial solution was inoculated, as a positive control, no meropenem was added to the 16th well No bacterial solution was added to the medicinal solution as a negative control. Place in a constant temperature and humidity incubator for 24 hours at 37°C and observe the results. The inoculated bacteria were divided into quality control bacteria and experimental bacteria, and two parallel experiments were performed for verification.
5.生长曲线的绘制5. Drawing of growth curve
将冰箱里冷冻保存的配制好的辣椒提取物溶液和美罗培南取出,待融化至室温使用。在超净工作台中,将美罗培南稀释到使终浓度为对耐药菌MIC的1/4浓度,辣椒提取物溶液不稀释;再将琼脂板上已过夜培养好的细菌,挑单个菌落接种于营养肉汤培养基增殖,并将细菌稀释至1.5×106CFU/mL。Take out the prepared capsicum extract solution and meropenem that have been frozen in the refrigerator, and let them thaw to room temperature for use. In the ultra-clean workbench, dilute meropenem so that the final concentration is 1/4 of the MIC for drug-resistant bacteria, and the pepper extract solution is not diluted; then pick a single colony and inoculate the bacteria that have been cultured overnight on the agar plate Nutrient broth was grown and bacteria were diluted to 1.5 x 10 6 CFU/mL.
实验分为四个组:不加药组、美罗培南组、辣椒提取物组、辣椒提取物联合美罗培南组,在无菌的96孔聚丙烯微量滴定板中,不加药组加入肉汤100μL和细菌稀释液100μL;美罗培南组加入美罗培南药液和肉汤各50μL和细菌稀释液100μL;辣椒提取物组加入辣椒提取物溶液和肉汤各50μL和细菌稀释液100μL;辣椒提取物联合美罗培南组加入美罗培南药液和辣椒提取物溶液各50μL和细菌稀释液100μL。每组各设三个重复,实验区外围各孔滴加200μL肉汤封闭防止污染。置恒温恒湿培养箱中37℃培养24h,共在5个时间点(0h、1h、6h、12h、24h)测量各实验孔的OD值,波长为600nm,计算出各组每个时间点的平均值,然后根据数据绘制出细菌的生长曲线图,并计算抑菌率。The experiment was divided into four groups: no drug group, meropenem group, capsicum extract group, capsicum extract combined with meropenem group. In a sterile 96-well polypropylene microtiter plate, the no drug group was added with 100 μL of broth and 100 μL of bacterial diluent; 50 μL of meropenem liquid and broth and 100 μL of bacterial diluent were added to the meropenem group; 50 μL of pepper extract solution and broth and 100 μL of bacterial diluent were added to the pepper extract group; In the ropenem group, 50 μL of meropenem liquid and capsicum extract solution and 100 μL of bacterial dilution were added. Three replicates were set up for each group, and 200 μL of broth was added dropwise to each well outside the experimental area to prevent contamination. Place in a constant temperature and humidity incubator for 24 hours at 37°C, and measure the OD value of each experimental well at 5 time points (0h, 1h, 6h, 12h, 24h). The average value, and then draw the growth curve of bacteria according to the data, and calculate the bacteriostatic rate.
6.肉汤微量稀释棋盘法测定体外抗菌活性6. Determination of Antibacterial Activity in Vitro by Broth Microdilution Checkerboard Method
根据生长曲线的结果,观察到辣椒提取物与美罗培南的联合抑菌率>50%。重新配制浓度为32mg/mL的辣椒提取物溶液,将美罗培南稀释到使终浓度为对耐药菌MIC的2倍浓度,将配制好的辣椒提取物溶液和美罗培南药液在加样器中分别用肉汤倍比稀释7个浓度梯度。According to the results of the growth curve, it was observed that the combined antibacterial rate of the capsicum extract and meropenem was >50%. Reconstitute the capsicum extract solution with a concentration of 32mg/mL, dilute the meropenem to make the final concentration twice the concentration of the MIC against drug-resistant bacteria, and put the prepared capsicum extract solution and meropenem liquid in the injector, respectively. Dilute 7 concentration gradients with broth.
在无菌的96孔聚丙烯微量滴定板中,每横排7个孔滴加美罗培南药液50μL,最后一孔不加药,从左至右各孔终浓度为:64μg/mL、32μg/mL、16μg/mL、8μg/mL、4μg/mL、2μg/mL、1μg/mL、0μg/mL;每竖排7个孔滴加辣椒提取物溶液50μL,最后一孔不加药,从上至下各孔终浓度为8mg/mL、4mg/mL、2mg/mL、1mg/mL、1/2mg/mL、1/4mg/mL、1/8mg/mL、0mg/mL。最后各孔滴加细菌稀释液100μL,放入恒温恒湿培养箱中培养18-24小时。第二天以肉眼观察无细菌生长的最低浓度为最小抑菌浓度(MIC)。分级抑菌浓度(FICI)指数值以确认受试辣椒提取物与美罗培南是否具有协同作用,FICI=(MIC辣椒提取物联合/MIC辣椒提取物单用)+(MIC美罗培南联合/MIC美罗培南单用)。In a sterile 96-well polypropylene microtiter plate, 50 μL of meropenem solution was added dropwise to each horizontal row of 7 wells, and no drug was added to the last well. The final concentrations of each well from left to right were: 64 μg/mL, 32 μg/mL , 16 μg/mL, 8 μg/mL, 4 μg/mL, 2 μg/mL, 1 μg/mL, 0 μg/mL; 50 μL of capsicum extract solution was added dropwise to each vertical row of 7 wells, and no drug was added to the last well, from top to bottom The final concentration of each well is 8mg/mL, 4mg/mL, 2mg/mL, 1mg/mL, 1/2mg/mL, 1/4mg/mL, 1/8mg/mL, 0mg/mL. Finally, 100 μL of bacterial dilution was added dropwise to each well, and placed in a constant temperature and humidity incubator for 18-24 hours. The lowest concentration at which no bacterial growth was observed with the naked eye on the second day was the minimum inhibitory concentration (MIC). Fractional inhibitory concentration (FICI) index value to confirm whether the tested pepper extract has a synergistic effect with meropenem, FICI=(MIC pepper extract combined/MIC pepper extract alone)+(MIC meropenem combined/MIC meropenem single use).
判定标准为:当FICI≤0.5时,判定为两者具有协同作用;当0.5<FICI<4.0时,判定为两者具有无关作用;当FICI>4.0时,判定为两者具有拮抗作用。The judging criteria are: when FICI≤0.5, it is judged that the two have synergistic effect; when 0.5<FICI<4.0, it is judged that the two have irrelevant effect; when FICI>4.0, it is judged that the two have antagonistic effect.
7结果与分析7 Results and Analysis
7.1美罗培南的MIC7.1 MIC of Meropenem
观察培养24h后的细菌的生长情况,孔中培养基变得浑浊或有沉淀形成,表明有细菌生长,记为“+”,如培养基澄清透明见不到细菌,表明没有细菌生长,记为“-”。Observe the growth of bacteria after 24 hours of cultivation. If the culture medium in the well becomes cloudy or precipitates form, it indicates that there is bacterial growth, which is recorded as "+". If the medium is clear and transparent and no bacteria can be seen, it indicates that there is no bacterial growth. "-".
质控菌的MIC结果见表1,美罗培南药物对质控菌的MIC为0.015625μg/mL,在其质控范围内。实验菌的MIC结果见表2,可见美罗培南对实验菌的MIC为32μg/mL。The MIC results of the quality control bacteria are shown in Table 1. The MIC of meropenem against the quality control bacteria was 0.015625 μg/mL, which was within the quality control range. The MIC results of the experimental bacteria are shown in Table 2. It can be seen that the MIC of meropenem against the experimental bacteria is 32 μg/mL.
表1质控菌的细菌生长结果Table 1 Bacterial growth results of quality control bacteria
表2实验菌的细菌生长结果Table 2 Bacterial growth results of experimental bacteria
7.2辣椒提取物联合美罗培南用药的生长曲线绘制7.2 Drawing the growth curve of capsicum extract combined with meropenem
根据测得的OD值绘制出生长曲线图,测得辣椒提取物与美罗培南联合用药具有较好的抑菌作用(图1),抑菌率大于65%,其抑菌率结果见表3。The growth curve was drawn according to the measured OD value. It was found that the combination of capsicum extract and meropenem had a good antibacterial effect (Figure 1), and the antibacterial rate was greater than 65%. The results of the antibacterial rate are shown in Table 3.
表3美罗培南与辣椒提取物联用的抑菌率Table 3 The antibacterial rate of meropenem combined with capsicum extract
7.3肉汤微量稀释棋盘法结果观察7.3 Observation of results of broth microdilution checkerboard method
对辣椒提取物进行肉汤微量稀释棋盘实验,以进一步验证辣椒提取物与美罗培南药物的合作关系。将观察到的棋盘各孔细菌生长结果用表格表示,“-”代表无细菌生长,“+”代表有细菌生长。A broth microdilution checkerboard experiment was performed on the pepper extract to further verify the cooperative relationship between the pepper extract and meropenem. The observed bacterial growth results in each well of the checkerboard are expressed in a table, "-" represents no bacterial growth, and "+" represents bacterial growth.
辣椒提取物与美罗培南联用的细菌生长结果见表4,由表4可知:The bacterial growth results of the combination of capsicum extract and meropenem are shown in Table 4, from which it can be seen that:
辣椒提取物单用时的MIC为>8mg/mL,联合时的MIC为2mg/mL;The MIC of capsicum extract when used alone is >8mg/mL, and the MIC when combined is 2mg/mL;
美罗培南单用时的MIC为32μg/mL,联合时的MIC为2μg/mL;The MIC of meropenem when used alone is 32 μg/mL, and the MIC when combined is 2 μg/mL;
所以FICI=2/>8+2/32,判定两者具有协同作用。Therefore, FICI=2/>8+2/32, it is determined that the two have a synergistic effect.
表4美罗培南与辣椒提取物联用的抗菌效果Table 4 Antibacterial effect of meropenem combined with capsicum extract
8.结论与讨论8. Conclusion and Discussion
通过生长曲线绘制实验和肉汤微量稀释棋盘法实验,发现辣椒提取物与美罗培南联合用药时具有协同作用,能够显著提高彼此对耐药菌的体外抑菌效果,且效果好于它们各自单独用药。Through the growth curve drawing experiment and the broth microdilution checkerboard experiment, it was found that the combination of capsicum extract and meropenem had a synergistic effect, which could significantly improve the antibacterial effect of each other on drug-resistant bacteria in vitro, and the effect was better than that of each drug alone .
结合本实验结果表明,辣椒提取物与美罗培南联合用药时,配比关系在一定范围内,具有很好的协同效果。本发明在探究辣椒提取物与抗生素联合用药时,通过大量实验研究了二者之间最优的配比关系,并得到了很好的抑菌配方。Combined with the results of this experiment, it shows that when the capsicum extract is combined with meropenem, the ratio relationship is within a certain range, and it has a good synergistic effect. When the present invention explores the combination of capsicum extract and antibiotics, the optimal ratio relationship between the two is studied through a large number of experiments, and a good antibacterial formula is obtained.
本实验筛选出的辣椒提取物能够联合美罗培南抑制其耐药菌的生长,这为进一步研究中西药联合对细菌的作用机制提供了方向,也对探究中草药提取物对其他耐药菌的体外抑菌作用有借鉴意义。The capsicum extract screened out in this experiment can combine with meropenem to inhibit the growth of its drug-resistant bacteria, which provides a direction for further research on the mechanism of action of the combination of Chinese and Western medicine on bacteria, and is also useful for exploring the in vitro inhibitory effect of Chinese herbal medicine extracts on other drug-resistant bacteria. The role of bacteria is of reference significance.
对比例comparative example
申请人在筛选中药提取物的过程中,将多种中药提取物与美罗培南联合后进行抑菌效果的比较,结果发现并不是每种组合都具有较好的抑菌效果或协同作用。在一些情况下,即使中药提取物本身具有抗菌作用,但与美罗培南联用后,并没有明显表现出较好的抑菌效果,也没有表现出联合用药后对美罗培南耐药菌的有效抑制作用或协同作用。In the process of screening Chinese medicine extracts, the applicant compared the antibacterial effects of various Chinese medicine extracts combined with meropenem, and found that not every combination has a good antibacterial effect or synergistic effect. In some cases, even though the traditional Chinese medicine extract itself has antibacterial effect, it does not show obvious antibacterial effect when combined with meropenem, nor does it show effective inhibition of meropenem-resistant bacteria after combined use effect or synergy.
按本发明的实验方法同法操作,桑叶提取物、杜仲叶提取物、黄芩苷分别与美罗培南联合应用时,并没有表现出协同作用。它们的生长曲线图分别见图2、图3和图4,FICI均在0.5~4.0之间,这表明没有产生协同增效作用。According to the same method as the experimental method of the present invention, when mulberry leaf extract, eucommia leaf extract, and baicalin were used in combination with meropenem, no synergistic effect was shown. Their growth curves are shown in Fig. 2, Fig. 3 and Fig. 4 respectively, and the FICIs are all between 0.5 and 4.0, which indicates that there is no synergistic effect.
结论:in conclusion:
本发明在研究中药提取物与美罗培南联合用药时,意外地发现当辣椒提取物在联合美罗培南用药时,对美罗培南耐药菌在体外有显著的抑制作用,且效果优于各自单独用药,因而美罗培南与所述辣椒提取物联合用药时具有明显的协同作用。本发明的抗菌组合物中,辣椒提取物与美罗培南抗生素联用具有增效和减毒优势。这样,每种物质在组合物中的相对用量会大大减少,进而减少可能的不良反应和副作用,提高用药安全性,同时还可以增加患者服用的依从性,从而保证疗效。When the present invention was studying the combination of traditional Chinese medicine extracts and meropenem, it was unexpectedly found that when the pepper extract was used in combination with meropenem, it had a significant inhibitory effect on meropenem-resistant bacteria in vitro, and the effect was better than that of each drug alone. Therefore, the combination of meropenem and the pepper extract has obvious synergistic effect. In the antibacterial composition of the present invention, the combined use of the pepper extract and the meropenem antibiotic has the advantages of synergism and attenuation. In this way, the relative dosage of each substance in the composition will be greatly reduced, thereby reducing possible adverse reactions and side effects, improving the safety of medication, and at the same time increasing the compliance of patients taking medication, thereby ensuring the curative effect.
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。Although, the present invention has been described in detail with general description, specific implementation and test above, but on the basis of the present invention, some modifications or improvements can be made to it, which will be obvious to those skilled in the art . Therefore, the modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the protection scope of the present invention.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111266650.7A CN114129635B (en) | 2021-10-28 | 2021-10-28 | Antibacterial composition containing capsicum extract and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111266650.7A CN114129635B (en) | 2021-10-28 | 2021-10-28 | Antibacterial composition containing capsicum extract and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114129635A CN114129635A (en) | 2022-03-04 |
CN114129635B true CN114129635B (en) | 2022-11-04 |
Family
ID=80395859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111266650.7A Active CN114129635B (en) | 2021-10-28 | 2021-10-28 | Antibacterial composition containing capsicum extract and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114129635B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103054833A (en) * | 2012-12-28 | 2013-04-24 | 湖南农业大学 | A formula of an antimicrobial oil emulsion microcapsule for veterinary use |
CN104610109A (en) * | 2009-11-12 | 2015-05-13 | 西格纳姆生物科学公司 | ANTI-BACTERIAL AGENTS and composites thereof |
KR102042151B1 (en) * | 2018-12-18 | 2019-11-07 | 한국식품연구원 | A composition as a prebiotic for improving intestinal microflora containing extract from pepper leaves |
-
2021
- 2021-10-28 CN CN202111266650.7A patent/CN114129635B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104610109A (en) * | 2009-11-12 | 2015-05-13 | 西格纳姆生物科学公司 | ANTI-BACTERIAL AGENTS and composites thereof |
CN103054833A (en) * | 2012-12-28 | 2013-04-24 | 湖南农业大学 | A formula of an antimicrobial oil emulsion microcapsule for veterinary use |
KR102042151B1 (en) * | 2018-12-18 | 2019-11-07 | 한국식품연구원 | A composition as a prebiotic for improving intestinal microflora containing extract from pepper leaves |
Non-Patent Citations (4)
Title |
---|
抗菌药物在兽医临床上的合理使用;孙志良,等;《湖南畜牧兽医》;19950430(第04期);第29-30页 * |
茶皂素与四种抗菌药物的体外联合抗菌效果研究;潘任桃,等;《动物医学进展》;20130820;第34卷(第08期);第119-122页 * |
药物对美罗培南抑制耐碳青霉烯类抗菌药物鲍曼不动杆菌的影响;于亮,等;《中华实验和临床感染病杂志(电子版)》;20121215;第06卷(第06期);第611-615页 * |
辣椒素类物质代谢生理研究进展;缪武,等;《辣椒杂志》;20050320(第01期);第1-4页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114129635A (en) | 2022-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Devhare et al. | Acid neutralizing capacity and antimicrobial potential of selected solvent extract from various indigenous plants | |
CN113577238B (en) | Application of Brazilian hematoxylin-potentiated polymyxin antibiotics in antibacterial effects on Escherichia coli | |
CN111096964A (en) | Combined application of quercetin and antibacterial drug | |
CN115869385A (en) | Application of natural product nocardone synergistic polymyxin in resisting gram-negative bacterial infection | |
CN119345170A (en) | A composition and its application in fighting multidrug-resistant Acinetobacter baumannii | |
Luo et al. | Study on the inhibitory effect of quercetin combined with gentamicin on the formation of Pseudomonas aeruginosa and its bioenvelope | |
CN114129635B (en) | Antibacterial composition containing capsicum extract and its application | |
CN116747221B (en) | Antibacterial composition and preparation method and application thereof | |
CN116139143B (en) | Application of natural medicine in preparation of medicine for resisting gram-positive bacteria | |
CN114042100B (en) | Antibacterial composition containing traditional Chinese medicine extract and application thereof | |
CN115778936A (en) | Application of usnic acid synergistic polymyxin in resisting gram-negative bacterial infection | |
CN114028418B (en) | Antibacterial composition containing chitosan oligosaccharide and application thereof | |
CN116509826B (en) | Application of magnolol or composition of magnolol and EGCG in inhibiting mycoplasma gallisepticum and mycoplasma synoviae | |
CN114272246A (en) | Application of uracil in the preparation of anti-infective drugs | |
Sari et al. | The Highest Dosage Combination Activity Screening from the Leaf Fraction of Melastoma malabathricum with Antibiotic Gentamicin and Ciprofloxacin | |
Roshanak et al. | Antibacterial activity of cLFchimera and its synergistic potential with antibiotics against some foodborne pathogens bacteria | |
CN113975304A (en) | Antibacterial composition containing isatidis extract and application thereof | |
CN112438989A (en) | Non-antibiotic antibacterial composition and application thereof | |
Khalifa | Study the Efficacy of Mono and Combination Therapy of Amoxicillin and Levofloxacin against S. aureus causing Respiratory Tract Infection in Rabbits | |
CN114129588B (en) | Antibacterial composition containing astragalus extract and application thereof | |
CN110870865A (en) | Application of sanguinarine in biofilm inhibition and clearance of multi-drug-resistant Providencia reinhardtii | |
CN118512423A (en) | Application of α-terpineol as a synergist in combating drug-resistant Enterobacteriaceae | |
CN115337320B (en) | Application of HyG in reducing MIC of imipenem high-drug-resistance pseudomonas aeruginosa | |
CN116509835B (en) | Application of taxifolin in preparation of drug for resisting mycoplasma gallisepticum and mycoplasma synoviae | |
CN116784446B (en) | A composition that synergistically inhibits Pseudomonas aeruginosa and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |